nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2004 | Controversies-Against

Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer’s disease in vivo?

verfasst von: Agneta Nordberg

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2004

Einloggen, um Zugang zu erhalten

Excerpt

Alzheimer’s disease (AD) is becoming a great health and socio-economic problem all over the world. There is an increasing consensus that the production and accumulation of amyloid protein is central to the pathogenesis of AD. Brain imaging has undergone rapid development and we are presently approaching the exciting possibility that it will allow the tracing of brain amyloid in AD patients. A key question, however, is whether amyloid plaque imaging reflects AD brain pathology. …

Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351–7.CrossRefPubMed

Thal DR, Rub U, Orantoes M, Braak H. Phases of A-beta deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791–800.PubMed

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256:184–5.PubMed

Schönheit B, Zarski R, Ohm T. Spatial and temporal relationship between plaques and tanges in Alzheimer-pathology. Neurobiol Aging 2004;25:697–711.PubMed

Nordberg A, Lundqvist H, Hartvig P, Lilja A, Långström B. Kinetic analysis of regional (S)(−)¹¹C-nicotine binding in normal and Alzheimer brains—in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995;1:21–7.

Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Azheimer’s disease. Neurology 1999;52:691–9.PubMed

Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science 2002;298:789–91.CrossRefPubMed

DeKosky ST, Ikonomovic MD, Styren SD, Becket L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in the hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145.CrossRefPubMed

Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between levels of amyloid beta-peptide in the brain and cognitive decline. J Am Med Assoc 2000;283:1571–7.CrossRef

10.

Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci U S A 2004;101:284–9.

11.

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and β-amyloid. Arch Neurol 2003;60:1696–702.CrossRefPubMed

12.

Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA. Development of an anti-A-beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer’s disease. Mol Neurobiol 1994;9:107–13.PubMed

13.

Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, et al. Molecular targeting Azheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002;11:315–29.CrossRefPubMed

14.

Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the betaamyloid protein of Alzheimer’s disease. Neurobiol Aging 1994;15:691–8.CrossRefPubMed

15.

Klunk WE, Engler H, Nordberg A, Bacskai BJ, Wang Y, Price J, et al. Imaging the pathology of Alzheimer’s diseases: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am 2003;13:781–9.PubMed

16.

Nordberg A. PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol 2004;3:519–27.CrossRefPubMed

17.

Shoghi-Jadid K, Small D, Agdeppa ED, Kepe V, Ercoli LM, Read S, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brain of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24–35.CrossRefPubMed

18.

Klunk EW, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 2004;55:306–19.

19.

Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, et al. Dialkylamino-6-acylmalonnonitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tool in Alzheimer’s disease. Mol Imaging Biol 2003;5:404–17.CrossRefPubMed

20.

Bresjanac M, Smid LM, Vovko TD, Petric A, Barrio JR, Popovic M. Molecular-imaging probe-2-(1-[6-[(fluoroethyl)(methyl)amino-2-naphthyl]ethylidene)malonitrile labels prion plaques in vitro. J Neurosci 2003;23:8029–33.

21.

Petersen RC, Doody R, Kurz A, Mohs RC, Rabin PV, Ritchie K, et al. Current concept in mild cognitive impairment. Arch Neurol 2001;58:1985–92.CrossRefPubMed

22.

Wolf H, Jelic V, Gertz HJ, Nordberg A, Juhlin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003;179:52–76.CrossRefPubMed

23.

Klunk WE, Price JC, Lopresti BJ, Debnath ML, Holt DP, Meltzer C, et al. Human amyloid-imaging studies in controls, mild cognitive impairment and Alzheimer’s disease using Pittsburgh Compound-B. Ninth international conference on Alzheimer’s disease and related disorders, Philadelphia, Pennsylvania. USA, 17–22 July 2004, abstr O-3-03-05.

24.

Nordberg A, Engler H, Blomqvist G, Almkvist O, Ausén B, Wall A, Långström B. Imaging of amyloid in vivo in MCI and AD patients. Ninth international conference on Alzheimer’s disease and related disorders, Philadelphia, Pennsylvania. USA, 17–22 July 2004, abstr O-3-03-08.

25.

Cummings JL. Alzheimer’s disease. N Engl J Med 2004;351:56–67.

26.

Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46–54.PubMed

27.

Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448–52.CrossRefPubMed

28.

Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In vivo measurement of activated microglia in dementia. Lancet 2001;11:461–7.CrossRef

29.

Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergström M, et al. Multitracer study with positron emission tomography in Creutzfeld-Jakob disease. Eur J Nucl Med Mol Imaging 2003;30:85–95.CrossRefPubMed

Titel: Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer’s disease in vivo?
verfasst von: Agneta Nordberg
Publikationsdatum: 01.11.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1677-8

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2004

Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases

Small animal PET: aspects of performance assessment

Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT?

In vitro detection of mdr1 mRNA in murine leukemia cells with 111In-labeled oligonucleotide

Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer’s disease in vivo?

99mTc-RBC scintigraphy showing portal vein aneurysm